Drug class
Genetic Disorder Therapy - SMN Protein Deficiency Treatment
The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class. Read more about Genetic Disorder Therapy - SMN Protein Deficiency Treatment
2 drugs in this class 2 manufacturers
Drugs in Genetic Disorder Therapy - SMN Protein Deficiency Treatment
EVRYSDI (risdiplam)
The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class.
This category encompasses disease-modifying agents designed to treat spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder marked by the loss of spinal motor neurons due to survival motor neuron (SMN) protein deficiency.
Therapies within this grouping, such as risdiplam and nusinersen, work by enhancing functional SMN protein production through modifying SMN2 pre-messenger RNA splicing, whereas associated gene replacement therapies directly supply functional SMN1 coding sequences.
Clinically, these agents improve motor function, halt disease progression, and increase survival in pediatric and adult patients with spinal muscular atrophy.
-
wv.gov
The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class
-
cigna.com
The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class
-
cigna.com
The phrase "Genetic Disorder Therapy - SMN Protein Deficiency Treatment" functions primarily as an administrative formulary and compendial classification rather than a formal pharmacologic drug class
-
nih.gov
This category encompasses disease-modifying agents designed to treat spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder marked by the loss of spinal motor neurons due to survival motor neuron (SMN) protein deficiency Therapies within this grouping, such as risdiplam and nusinersen, work by enhancing functional SMN protein production through modifying SMN2 pre-messenger RNA splicing, whereas associated gene replacement therapies directly supply functional SMN1 coding seq...
-
curesma.org
This category encompasses disease-modifying agents designed to treat spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder marked by the loss of spinal motor neurons due to survival motor neuron (SMN) protein deficiency
-
nih.gov
This category encompasses disease-modifying agents designed to treat spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder marked by the loss of spinal motor neurons due to survival motor neuron (SMN) protein deficiency
-
smanewstoday.com
Therapies within this grouping, such as risdiplam and nusinersen, work by enhancing functional SMN protein production through modifying SMN2 pre-messenger RNA splicing, whereas associated gene replacement therapies directly supply functional SMN1 coding sequences
-
nm.org
Clinically, these agents improve motor function, halt disease progression, and increase survival in pediatric and adult patients with spinal muscular atrophy
-
delveinsight.com
Clinically, these agents improve motor function, halt disease progression, and increase survival in pediatric and adult patients with spinal muscular atrophy
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.